Medmira (MIR) AI Stock Analysis

• Market Cap: C$60.66M
• Dividend Yield: N/A
• Average Volume (3M): 39.46K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.41
• Revenue Growth: -32.14%
• EPS Growth: -52.38%
• Country: CA
• Employees: 65
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 758,307,070
• 10 Day Avg. Volume: 40,880
• 30 Day Avg. Volume: 39,463
• PEG Ratio: 3.68
• Price to Book (P/B): -2.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -15.45
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: C$0.00 ▼(-100.00%Downside)

Medmira's overall stock score is primarily constrained by its poor financial performance and valuation metrics, highlighting significant risks and operational inefficiencies. While the technical analysis indicates neutral momentum, the recent corporate partnership offers a positive outlook by potentially expanding market reach and improving revenue streams.

Medmira Business Overview & Revenue Model

Company Description

MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, the Asia Pacific, and internationally. The company offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product to perform preliminary screening of HIV and hepatitis. It also provides Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics; and Reveal HP, a rapid H. Pylori antibody test, which detects helicobacter pylori (HP) antibodies in serum, plasma, or whole blood produced in response to HP infection. In addition, the company offers VYRA CoV2 that detects antigens specific for the nucleocapsid region of SARS-CoV-2; VYRA CoV2Flu, a combination viral nucleocapsid antigen tests that detects infection caused by SARS-CoV-2, and Influenza A and Influenza B; and REVEALCOVID-19, an antibody test. It sells its products through a network of medical distributors and strategic business development partners to customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.

How the Company Makes Money

Medmira makes money through the sale of its rapid diagnostic test kits to healthcare providers, clinics, and distributors worldwide. The company's revenue model is primarily based on product sales, with its rapid tests being the key revenue streams. Medmira collaborates with various distribution partners to expand its market reach and accessibility of its products. Additionally, the company seeks to enhance its earnings through strategic partnerships and licensing agreements that allow it to leverage its proprietary technology in new markets or applications.

Medmira Financial Statement Overview

Summary

Medmira faces severe financial challenges, with declining revenues, negative gross profit margins, and negative equity. Operational inefficiencies and high financial leverage raise concerns about solvency and sustainability.

Income Statement

Medmira's income statement reveals significant challenges. The company is experiencing declining revenue growth with a negative gross profit margin, indicating cost inefficiencies in production. Net profit margin is negative, suggesting sustained losses, and both EBIT and EBITDA margins are negative, highlighting operational difficulties.

Balance Sheet

The balance sheet shows high financial leverage with a negative stockholders' equity, indicating potential solvency issues. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is also negative, reflecting financial instability. These factors suggest a high-risk financial position.

Cash Flow

Cash flow analysis shows negative free cash flow, indicating the company is not generating sufficient cash to cover capital expenditures. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting revenue into cash. However, the cash flow from financing activities is positive, indicating dependency on external funding to support operations.

Breakdown
TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
276.73K	412.57K	432.53K	952.13K	2.14M	919.07K
	Gross Profit
-8.96K	226.49K	-434.91K	304.03K	1.72M	572.28K
	EBIT
-3.62M	-2.57M	-1.94M	-1.45M	-184.23K	-1.30M
	EBITDA
-3.13M	-2.13M	-1.58M	-1.07M	185.30K	-1.13M
	Net Income Common Stockholders
-4.46M	-3.33M	-2.68M	-1.83M	-675.80K	-2.05M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
295.62K	2.10M	13.18K	33.46K	-2.30M	401.86K
	Total Assets
4.20M	6.07M	3.65M	3.83M	3.89M	3.40M
	Total Debt
9.49M	9.56M	9.27M	8.30M	11.54M	11.91M
	Net Debt
9.19M	7.46M	9.26M	8.27M	13.84M	11.51M
	Total Liabilities
24.74M	24.11M	18.68M	16.19M	19.61M	18.96M
	Stockholders Equity
-20.54M	-18.04M	-15.03M	-12.36M	-15.72M	-15.56M
Cash Flow		Free Cash Flow
-4.17M	-3.68M	-1.27M	-1.95M	-541.19K	-417.78K
	Operating Cash Flow
-3.42M	-2.94M	-1.27M	-1.88M	-504.64K	-315.90K
	Investing Cash Flow
-746.19K	-742.53K	-1.27K	-69.72K	-36.55K	-101.88K
	Financing Cash Flow
3.61M	5.77M	1.25M	1.99M	139.32K	730.74K

Medmira Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MIR, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.09, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.45 is Neutral, neither overbought nor oversold. The STOCH value of 38.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MIR.

Medmira Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COV	77 Outperform	C$64.43M	16.70	14.51%	―	28.97%	―
MBX	68 Neutral	C$42.24M	25.86	5.32%	―	-4.67%	-60.94%
Sector *	54 Neutral	$5.37B	3.35	-45.10%	2.79%	16.77%	-0.01%
MIR	46 Neutral	C$60.66M	―		―	-32.14%	-52.38%
ONCY		$37.01M	―	-211.24%	―	―	―
SVA	33 Underperform	C$54.20M	―	248.46%	―	―	32.71%
HBP	33 Underperform	C$68.96M	―	685.26%	―	―	-50.29%

Medmira Corporate Events

MedMira Partners with Lovell to Enhance Federal Access to Rapid HIV Testing

MedMira Inc. has partnered with Lovell Government Services to expand access to its Reveal® G4 HIV-1/2 rapid test within federal healthcare systems, including the Veterans Health Administration and the Military Health System. This collaboration allows MedMira to leverage Lovell’s status as a Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor, facilitating the procurement of their products through various federal contracting systems. The partnership is expected to enhance MedMira’s market reach and streamline the acquisition process for government agencies, thereby supporting federal procurement goals and improving healthcare delivery for veterans.

MedMira Achieves Regulatory Milestones Amidst Financial Challenges in Q2 FY2025

MedMira Inc. reported its Q2 FY2025 financial results, highlighting significant regulatory achievements, including Health Canada approval for its Multiplo® Rapid TP/HIV Test and Reveal® Rapid HIV Test. The company expanded its market reach through new distribution agreements in Canada and the USA. Despite recording a net loss and increased operating expenses due to clinical trials, MedMira anticipates revenue growth driven by the demand for its testing solutions. The company is also pursuing regulatory clearance for home testing applications, which could further enhance its market position.